Emergent BioSolutions (EBS) Return on Invested Capital (2012 - 2021)

Emergent BioSolutions' Return on Invested Capital history runs 6 years deep, the most recent figure standing at 0.18% for Q1 2021.

• On a quarterly basis, Return on Invested Capital rose 17.0% year-over-year to 0.18% in Q1 2021; TTM through Mar 2021 was 0.18%, a 17.0% increase from a year earlier, with the FY2019 full-year figure at 0.18%, changed N/A from the prior year.
• Return on Invested Capital advanced to 0.18% in Q1 2021 per EBS's latest filing, from 0.13% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.18% in Q1 2021 and bottomed at 0.0% in Q2 2019.
• The 3-year median for Return on Invested Capital is 0.02% (2019), against an average of 0.04%.
• Across the five-year window, Return on Invested Capital declined 1 bps in 2020 and gained 17 bps in 2021, its largest moves.
• Year by year, Return on Invested Capital stood at 0.0% in 2019, then soared by 2874 bps to 0.13% in 2020, then surged by 34 bps to 0.18% in 2021.
• Per Business Quant, the three latest EBS Return on Invested Capital figures stand at 0.18% (Q1 2021), 0.13% (Q4 2020), and 0.04% (Q3 2020).